Abpro Holdings (ABPO) EBIT (2022 - 2026)
Abpro Holdings' (ABPO) quarterly EBIT came in at -$933000.0 in Q1 2026, up 68.46% YoY from -$553845.9 in Q1 2025, and up 50.82% on a QoQ basis from -$1.9 million in Q4 2025.
Abpro Holdings (ABPO) EBIT (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of EBIT data on file, last reported at -$933000.0 in Q1 2026.
- Quarterly EBIT rose 68.46% year-over-year to -$933000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (up 35.73% YoY) and the FY2025 annual result came in at -$8.5 million, up 14.81% from the prior year.
- EBIT improved to -$933000.0 in Q1 2026, from -$1.9 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$315247.0 in Q3 2023 to a low of -$10.5 million in Q4 2023.
- A 5-year average of -$1.9 million and a median of -$1.3 million in 2025 frame the typical range for EBIT.
- Annual changes were most pronounced in 2023 — EBIT tumbled 1679.15% — and 2024, when it soared 73.54%.
- Tracing ABPO's EBIT over 5 years: stood at -$588645.0 in 2022, then plunged by 1679.15% to -$10.5 million in 2023, then soared by 73.54% to -$2.8 million in 2024, then surged by 31.54% to -$1.9 million in 2025, then surged by 50.82% to -$933000.0 in 2026.
- The last three EBIT figures came in at -$933000.0 (Q1 2026), -$1.9 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - | -1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -933,000.00 |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -1.34 Mn |
| Jun 30, 2025 | -2.26 Mn |
| Mar 31, 2025 | -2.96 Mn |
| Dec 31, 2024 | -2.77 Mn |
| Sep 30, 2024 | -1.93 Mn |
| Jun 30, 2024 | -2.34 Mn |
| Mar 31, 2024 | -2.88 Mn |
| Dec 31, 2023 | -10.47 Mn |
| Sep 30, 2023 | -315,247.00 |
| Jun 30, 2023 | -420,341.00 |
| Mar 31, 2023 | -537,558.00 |
| Dec 31, 2022 | -588,645.00 |
| Sep 30, 2022 | -533,796.00 |
| Jun 30, 2022 | -434,432.00 |
| Mar 31, 2022 | -493,537.00 |